[go: up one dir, main page]

WO2011160798A1 - Compositions pharmaceutiques comprenant de l'imatinib ou un sel pharmaceutiquement acceptable de celui-ci et procédés pour la fabrication de celles-ci - Google Patents

Compositions pharmaceutiques comprenant de l'imatinib ou un sel pharmaceutiquement acceptable de celui-ci et procédés pour la fabrication de celles-ci Download PDF

Info

Publication number
WO2011160798A1
WO2011160798A1 PCT/EP2011/003020 EP2011003020W WO2011160798A1 WO 2011160798 A1 WO2011160798 A1 WO 2011160798A1 EP 2011003020 W EP2011003020 W EP 2011003020W WO 2011160798 A1 WO2011160798 A1 WO 2011160798A1
Authority
WO
WIPO (PCT)
Prior art keywords
tablet
imatinib
core
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/003020
Other languages
English (en)
Inventor
Sayisiva Prasad Ravula
Anand Kumar Mamidi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zaklady Farmaceutyczne Polpharma SA
Original Assignee
Zaklady Farmaceutyczne Polpharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zaklady Farmaceutyczne Polpharma SA filed Critical Zaklady Farmaceutyczne Polpharma SA
Priority to EA201300034A priority Critical patent/EA029416B1/ru
Priority to EP11733997.8A priority patent/EP2582362A1/fr
Priority to PL402710A priority patent/PL234542B1/pl
Publication of WO2011160798A1 publication Critical patent/WO2011160798A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient

Definitions

  • compositions comprising imatinib or pharmaceutically acceptable salt thereof and processes for the manufacture thereof.
  • the invention relates to pharmaceutical compositions comprising imatinib or pharmaceutically acceptable salt thereof as active ingredient and processes for the manufacture thereof.
  • Imatinib in the form of methanesulfonate is marketed under trade name Glivec and is indicated for the treatment of chronic myeloid leukaemia, Philadelphia chromosome positive acute lymphoblastic leukaemia, myelodysplastic or myeloproliferative diseases, advanced hypereosinophilic syndrome or chronic eosinophilic leukaemia, gastrointestinal stromal tumours and dermatofibrosarcoma protuberans.
  • Imatinib is administered orally to patients in daily doses of up to 800 mg depending on the condition of the patient. Imatinib was first launched in the doses of 50 mg and 100 mg in the form of capsules which were substantially disadvantageous to patients who had to be administered several capsules at the same time.
  • EP 1501485A1 disclosed tablets with high load of imatinib and defined contents of excipients were described.
  • the excipients comprise at least one binder, at least one disintegrant, at least one glidant and at least one lubricant.
  • the process for obtaining the tablets disclosed in EP 1501485A1 employs the steps of wet granulation of imatinib blended with pharmaceutically acceptable excipients, including a binder, addition of further pharmaceutically acceptable excipients to the thus obtained granulate and compressing the mixture to tablet.
  • EP 1762230A1 discloses the preparation of pharmaceutical compositions comprising imatinib or its salt by dry-granulation processes. All the examples disclose dry-granulation processes which employ the use of imatinib or pharmaceutically acceptable salt thereof with at least one binder. The most important disadvantage of dry-granulation method is cost of the equipment which renders the technology very expensive and uncommon.
  • the aim of the present invention is to develop a new oral tablet comprising imatinib or pharmaceutically acceptable salt thereof as active ingredient that can be produced in a simple manner without using expensive technology as disclosed in the prior art. Additionally, to afford patient compliance, the tablet according to the invention should preferably have the active ingredient present in a high amount in the tablet in order to obtain smaller tablets, more suitable especially for patients who have problems with swallowing.
  • tablets comprising imatinib or pharmaceutically acceptable salt thereof as active ingredient in the core of the tablet can be obtained without using any binder in the core of the tablet.
  • wet granulation of imatinib or pharmaceutically acceptable salt thereof without the use of any binder can afford granulates suitable for obtaining a tablet comprising imatinib or pharmaceutically acceptable salt thereof and such obtained tablets have better bioavailability by exhibiting shorter disintegration time.
  • the active ingredient is preferably present in a high amount in the core of the tablet.
  • the tablet according to the present invention comprises imatinib or pharmaceutically acceptable salt thereof as active ingredient and does not comprise any binder in the core of the tablet.
  • the tablet further comprises extragranularly at least one disintegrant.
  • the tablet further comprises extragranularly at least one glidant and/or lubricant.
  • the binder which is not used in the present invention is a substance used to impart cohesive qualities to the powdered material and impart a cohesiveness to the tablet formulation that ensures the tablet remaining intact after compression.
  • binder and binding agent means the same and can be used interchangeably.
  • binding agents which are not used in the present invention: hydroxyethyl cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose, povidone, starch.
  • the tablet according to the present invention comprises imatinib or pharmaceutically acceptable salt thereof as active ingredient in the core of the tablet preferably in a high amount, preferably from 55% to 93% by weight based on the total mass of the core of the tablet, more preferably from 60% to 90%, most preferably from 65% to 85%.
  • the tablet comprises from 50 to 75% by weight of imatinib base based on the total mass of the total tablet and comprises at least one pharmaceutically acceptable excipient without a binding agent.
  • the core of the tablet consists of imatinib or pharmaceutically acceptable salt thereof, at least one disintegrant, at least one glidant and/or lubricant.
  • the tablet according to the present invention preferably comprises extragranularly at least one disintegrant preferably selected from the group consisting of crospovidone, croscarmellose sodium, sodium starch glycolate and mixtures thereof.
  • the disintegrant is preferably present in the core of the tablet in an amount from 7% to 30% by weight based on the total mass of the core of the tablet, more preferably from 10% to 25%, most preferably from 12% to 20%.
  • the tablet according to the present invention preferably comprises extragranularly at least one glidant and/or lubricant.
  • Some of the glidants and the lubricants can be used interchangeably as some of them can exhibit both properties.
  • the glidant is preferably selected from the group consisting of colloidal silicon dioxide, calcium silicate, magnesium trisilicate and mixtures thereof.
  • the glidant might be preferably present in the core of the tablet in an amount from 0.1% to 10% by weight based on the total mass of the core of the tablet, more preferably from 0.5% to 8%, most preferably from 1% to 5%.
  • the lubricant is preferably selected from the group consisting of sodium stearyl fumarate, talc, magnesium stearate, calcium stearate and zinc stearate and mixtures thereof.
  • the lubricant is preferably present in the core of the tablet in an amount from 0.1% to 5% by weight based on the total mass of the core of the tablet, more preferably from 0.5% to 4%, most preferably from 1% to 3%.
  • the tablet according to the present invention comprises imatinib or pharmaceutically acceptable salt thereof as the active ingredient, preferably imatinib methanesulfonate also known as imatinib mesylate.
  • the core of the tablet of the present invention is understood to mean an uncoated tablet.
  • the core of the tablet of the present invention can be coated using pharmaceutically acceptable coating mixtures.
  • the invention is directed to a process for preparation of a pharmaceutical composition comprising imatinib or pharmaceutically acceptable salt thereof as active ingredient not comprising any binder.
  • the process according to the present invention comprises the step of wet granulation of imatinib or pharmaceutically acceptable salt thereof without any binder, preferably without any pharmaceutically acceptable excipient. Further steps of the process preferably comprise blending the granules comprising imatinib or pharmaceutically acceptable salt thereof with pharmaceutically acceptable extragranular excipients.
  • the process according to the present invention preferably employs the active ingredient in an amount from 55% to 93% by weight based on the total mass of the pharmaceutical composition, more preferably from 60% to 90%, most preferably from 65% to 85%.
  • imatinib is employed in the form of imatinib methanesulfonate also known as imatinib mesylate.
  • the process employs from 50 to 75% by weight of imatinib or pharmaceutically acceptable salt thereof where the range from 50 to 75% by weight corresponds to imatinib base based on the total mass of the pharmaceutical composition without a binding agent.
  • the process according to the present invention preferably employs pharmaceutically acceptable extragranular excipients, preferably at least one disintegrant, more preferably also at least one glidant and/or lubricant.
  • the process employs imatinib or pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients consisting of at least one disintegrant, at least one glidant and/or lubricant.
  • the disintegrant is preferably selected from the group consisting of crospovidone, croscarmellose sodium, sodium starch glycolate and mixtures thereof.
  • the disintegrant is employed in the process of the present invention in an amount from 7% to 30% by weight based on the total mass of the pharmaceutical composition, more preferably from 10% to 25%, most preferably from 12% to 20%.
  • the process according to the present invention preferably employs at least one glidant and/or lubricant.
  • Some of the glidants and the lubricants can be used interchangeably as some of them can exhibit both properties.
  • the glidant is preferably selected from the group consisting of colloidal silicon dioxide, calcium silicate, magnesium trisilicate and mixtures thereof.
  • the glidant is employed in the process in an amount from 0.1% to 10% by weight based on the total mass of the pharmaceutical composition, more preferably from 0.5% to 8%, most preferably from 1% to 5%.
  • the lubricant is preferably selected from the group consisting of sodium stearyl fumarate, talc, magnesium stearate, calcium stearate and zinc stearate and mixtures thereof.
  • the lubricant is employed in the process in an amount from 0.1% to 5% by weight based on the total mass of the pharmaceutical composition, more preferably from 0.5% to 4%, most preferably from 1% to 3%.
  • the process comprises the following steps: a) wet granulation of imatinib or pharmaceutically acceptable salt thereof without any binder, preferably without any pharmaceutically acceptable excipient using purified water; b) drying and preferably sieving the granules as obtained in step a); c) sieving and blending pharmaceutically acceptable extragranular excipients comprising at least one disintegrant and at least one glidant and/or lubricant; d) adding the extragranular mixture as obtained in step c) to granules as obtained in step b) and blending thus obtained mixture e) compressing the mixture as obtained in step d) to tablets.
  • the process comprises the following steps: i) self granulating the imatinib methanesulfonate with the aid of a solvent to obtain the granules, the solvent preferably is purified water; ii) mixing the granules obtained in the step (i) with at least one disintegrant, at least one glidant and/or lubricant; iii) compressing the mixture obtained in step (ii) to form the tablets and iv) optionally coating the tablets with a film coating agent to form the film coated tablets.
  • the process according to the present invention preferably affords the pharmaceutical composition in the form of a core of a tablet.
  • the process of the present invention can afford the core of the tablet described above.
  • the process according to the present invention preferably comprises the step of coating the pharmaceutical composition, preferably a core of the tablet, using conventional coating mixtures and standard equipment.
  • the process according to the present invention preferably employs a fluid bed granulator or a high shear mixer, more preferably a high shear mixer for the granulation process as described in step a) or i), an oven tray dryer or a fluid bed granulator for the drying process as described in step b), a V-blender or a bin mixer for blending as mentioned in steps c) or ii) and d), and a single punch tableting machine or a rotary tableting machine for compressing to tablets as mentioned in step d) or iii).
  • the weighed amount of imatinib mesylate is wet granulated in a high shear mixer using purified water.
  • granules are dried in a tray dryer and sieved through 20 mesh sieve.
  • the weighed amount of extragranular excipients croscarmellose sodium, colloidal silicon dioxide, sodium stearyl fumarate and talc
  • croscarmellose sodium, colloidal silicon dioxide, sodium stearyl fumarate and talc are sieved through 30 mesh sieve and blended for 3 minutes using bicone blender.
  • the granules and the blended mixture are mixed for 5 minutes using bicone blender and compressed into tablets using oblong 16.5x7mm punches.
  • the resulting tablets have the weight of 582 mg.
  • Example 5 Procedure identical to that in Example 1. The resulting tablets have the weight of 544 mg. Example 5
  • Example 6 the tablets obtained in Example 6 were coated with coating mixture of hypromellose, macrogol, talc, iron oxide red and iron oxide yellow using a standard method. The tablet after coating weighs 593.5 mg.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques comprenant de l'imatinib ou un sel pharmaceutiquement acceptable de celui-ci et des procédés pour la fabrication de celles-ci.
PCT/EP2011/003020 2010-06-21 2011-06-17 Compositions pharmaceutiques comprenant de l'imatinib ou un sel pharmaceutiquement acceptable de celui-ci et procédés pour la fabrication de celles-ci Ceased WO2011160798A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EA201300034A EA029416B1 (ru) 2010-06-21 2011-06-17 Таблетка, содержащая иматиниб или его фармацевтически приемлемую соль, и способ ее получения
EP11733997.8A EP2582362A1 (fr) 2010-06-21 2011-06-17 Compositions pharmaceutiques comprenant de l'imatinib ou un sel pharmaceutiquement acceptable de celui-ci et procédés pour la fabrication de celles-ci
PL402710A PL234542B1 (pl) 2010-06-21 2011-06-17 Sposób otrzymywania kompozycji farmaceutycznej zawierającej imatinib lub jego farmaceutycznie dopuszczalną sól

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1732/CHE/2010 2010-06-21
IN1732CH2010 2010-06-21
EP10460039 2010-09-20
EP10460039.0 2010-09-20

Publications (1)

Publication Number Publication Date
WO2011160798A1 true WO2011160798A1 (fr) 2011-12-29

Family

ID=44358103

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/003020 Ceased WO2011160798A1 (fr) 2010-06-21 2011-06-17 Compositions pharmaceutiques comprenant de l'imatinib ou un sel pharmaceutiquement acceptable de celui-ci et procédés pour la fabrication de celles-ci

Country Status (4)

Country Link
EP (1) EP2582362A1 (fr)
EA (1) EA029416B1 (fr)
PL (1) PL234542B1 (fr)
WO (1) WO2011160798A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012176014A1 (fr) * 2011-06-22 2012-12-27 Natco Pharma Limited Composition pharmaceutique orale de mésylate d'imatinib et son procédé de préparation
JP2013245202A (ja) * 2012-05-28 2013-12-09 Nipro Corp 医薬組成物
EP2749271A1 (fr) * 2012-12-31 2014-07-02 Deva Holding Anonim Sirketi Procédé optimisée de fabrication et formulation pharmaceutique de l'imatinib
WO2014139836A1 (fr) * 2013-03-15 2014-09-18 Pharmaceutical Oriented Services Ltd Compositions pharmaceutiques à base d'imatinib
EP2803352A1 (fr) 2013-05-14 2014-11-19 Hetero Research Foundation Compositions d'imatinib
CN104414988A (zh) * 2013-08-28 2015-03-18 山东新时代药业有限公司 一种达沙替尼片剂及其制备工艺
WO2017129624A1 (fr) * 2016-01-25 2017-08-03 Krka, D.D., Novo Mesto Composition pharmaceutique à dispersion rapide comprenant un inhibiteur de la tyrosine kinase
EP3257499A1 (fr) 2016-06-17 2017-12-20 Vipharm S.A. Procédé pour la préparation de capsules de méthanesulfonate d'imatinib
WO2019016673A3 (fr) * 2017-07-20 2019-03-07 Kashiv Pharma Llc Composition pharmaceutique stable d'imatinib à administration par voie orale
WO2021009695A1 (fr) * 2019-07-15 2021-01-21 Novartis Ag Formulations de (s)-3-amino-6-méthoxy-n-(3,3,3-trifluoro-2-hydroxy-2-méthylpropyl)-5-(trifluorométhyl)picolinamide
CN114259497A (zh) * 2016-07-26 2022-04-01 江苏豪森药业集团有限公司 氨基嘧啶类化合物的药物组合物及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564409A1 (fr) 1992-04-03 1993-10-06 Ciba-Geigy Ag Dérivés de pyrimidine et procédé pour leur préparation
EP1501485A1 (fr) 2002-04-23 2005-02-02 Novartis AG Comprime a forte charge en substance medicamenteuse
EP1762230A1 (fr) 2005-08-15 2007-03-14 Siegfried Generics International AG Tablette enrobé ou granulate comprenante un pyridylpyrimidine
US20090087489A1 (en) * 2007-09-25 2009-04-02 Bella Gerber Imatinib compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564409A1 (fr) 1992-04-03 1993-10-06 Ciba-Geigy Ag Dérivés de pyrimidine et procédé pour leur préparation
EP1501485A1 (fr) 2002-04-23 2005-02-02 Novartis AG Comprime a forte charge en substance medicamenteuse
EP1501485B1 (fr) * 2002-04-23 2007-09-26 Novartis AG Comprime a forte charge en substance medicamenteuse
EP1762230A1 (fr) 2005-08-15 2007-03-14 Siegfried Generics International AG Tablette enrobé ou granulate comprenante un pyridylpyrimidine
US20090087489A1 (en) * 2007-09-25 2009-04-02 Bella Gerber Imatinib compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Pharmaceutical compositions containing Imatinib", RESEARCH DISCLOSURE, MASON PUBLICATIONS, HAMPSHIRE, GB, vol. 542, no. 6, 1 June 2009 (2009-06-01), pages 573, XP007139052, ISSN: 0374-4353 *
"Stable Tablet Formulation containing more than 80% of Imatinib mesylate", IP.COM JOURNAL, IP.COM INC., WEST HENRIETTA, NY, US, 19 February 2008 (2008-02-19), XP013123894, ISSN: 1533-0001 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9750700B2 (en) 2011-06-22 2017-09-05 Natco Pharma Limited Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
WO2012176014A1 (fr) * 2011-06-22 2012-12-27 Natco Pharma Limited Composition pharmaceutique orale de mésylate d'imatinib et son procédé de préparation
JP2013245202A (ja) * 2012-05-28 2013-12-09 Nipro Corp 医薬組成物
EP2749271A1 (fr) * 2012-12-31 2014-07-02 Deva Holding Anonim Sirketi Procédé optimisée de fabrication et formulation pharmaceutique de l'imatinib
WO2014139836A1 (fr) * 2013-03-15 2014-09-18 Pharmaceutical Oriented Services Ltd Compositions pharmaceutiques à base d'imatinib
EP2803352A1 (fr) 2013-05-14 2014-11-19 Hetero Research Foundation Compositions d'imatinib
EP2803353A1 (fr) 2013-05-14 2014-11-19 Hetero Research Foundation Compositions d'imatinib
CN104414988A (zh) * 2013-08-28 2015-03-18 山东新时代药业有限公司 一种达沙替尼片剂及其制备工艺
WO2017129624A1 (fr) * 2016-01-25 2017-08-03 Krka, D.D., Novo Mesto Composition pharmaceutique à dispersion rapide comprenant un inhibiteur de la tyrosine kinase
EA035891B1 (ru) * 2016-01-25 2020-08-27 КРКА, д.д., НОВО МЕСТО Быстродиспергируемая фармацевтическая композиция, включающая ингибитор тирозинкиназы
EP3257499A1 (fr) 2016-06-17 2017-12-20 Vipharm S.A. Procédé pour la préparation de capsules de méthanesulfonate d'imatinib
CN114259497A (zh) * 2016-07-26 2022-04-01 江苏豪森药业集团有限公司 氨基嘧啶类化合物的药物组合物及其制备方法
WO2019016673A3 (fr) * 2017-07-20 2019-03-07 Kashiv Pharma Llc Composition pharmaceutique stable d'imatinib à administration par voie orale
US11285152B2 (en) 2017-07-20 2022-03-29 Kashiv Biosciences, Llc Stable oral pharmaceutical composition of imatinib
WO2021009695A1 (fr) * 2019-07-15 2021-01-21 Novartis Ag Formulations de (s)-3-amino-6-méthoxy-n-(3,3,3-trifluoro-2-hydroxy-2-méthylpropyl)-5-(trifluorométhyl)picolinamide
CN114007616A (zh) * 2019-07-15 2022-02-01 诺华股份有限公司 (s)-3-氨基-6-甲氧基-n-(3，3，3-三氟-2-羟基-2-甲基丙基)-5-(三氟甲基)吡啶甲酰胺的配制品
JP2022541178A (ja) * 2019-07-15 2022-09-22 ノバルティス アーゲー （ｓ）－３－アミノ－６－メトキシ－ｎ－（３，３，３－トリフルオロ－２－ヒドロキシ－２－メチルプロピル）－５－（トリフルオロメチル）ピコリンアミド製剤
US11865109B2 (en) 2019-07-15 2024-01-09 Novartis Ag Formulations of (S)-3-amino-6-methoxy-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide

Also Published As

Publication number Publication date
EA029416B1 (ru) 2018-03-30
EP2582362A1 (fr) 2013-04-24
PL402710A1 (pl) 2013-09-30
EA201300034A1 (ru) 2013-05-30
PL234542B1 (pl) 2020-03-31

Similar Documents

Publication Publication Date Title
EP2582362A1 (fr) Compositions pharmaceutiques comprenant de l'imatinib ou un sel pharmaceutiquement acceptable de celui-ci et procédés pour la fabrication de celles-ci
EP3606511B1 (fr) Composition pharmaceutique contenant du lenvatinib mesylate
NO341027B1 (no) Tablett med høyt medikamentinnhold og fremgangsmåte for fremstilling derav
KR101977785B1 (ko) 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법
JP2016536285A (ja) アムロジピン及びバルサルタンを含む安定な医薬組成物
CA2662265A1 (fr) Compositions d'imatinib
EP3860606B1 (fr) Composition pharmaceutique comprenant esylate ou tosylate de lenvatinib
AU2019232937B2 (en) Ceritinib formulation
JP2009524658A (ja) レベチラセタム製剤、及びそれらの製造方法
KR20140041641A (ko) 이토프라이드 염산염을 함유하는 제어 방출성 경구 제제의 조성물 및 그의 제조방법
KR101938872B1 (ko) 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법
EP2497464A2 (fr) Composition pharmaceutique de l'imatinibe methanesulphonate et son procédé de fabrication
WO2010046418A1 (fr) Composition pharmaceutique contenant du lévétiracétam
WO2011161689A1 (fr) Comprimé pharmaceutique de mésylate d'imatinib
KR20180103090A (ko) 퀴놀린 유도체 또는 그의 염을 포함하는 약학적 조성물의 제조 방법
KR101944085B1 (ko) 발사르탄 함유 고형 경구제형 및 그 제조방법
AU2014288866A1 (en) Oral pharmaceutical compositions comprising Imatinib mesylate
KR20120134545A (ko) 안정성 및 함량 균일성이 개선된 속방성 약학 조성물의 제조방법
JP2024531701A (ja) ベムペド酸医薬組成物
WO2017078647A1 (fr) Compositions pharmaceutiques d'imatinib
JP2019189554A (ja) 溶出性を改善させた医薬組成物
KR20160034351A (ko) 리팜피신, 이소니아지드, 에탐부톨 및 피라진아미드를 포함하는 항결핵 조성물 및 그의 제조 방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11733997

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: P.402710

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 2011733997

Country of ref document: EP

Ref document number: 201300034

Country of ref document: EA